Glaukos Corporation

GKOS trades at a 52-week high of $152.62 with an RSI of 70.7, signaling overbought territory, yet the stock commands a $6.8B valuation despite posting losses (P/E unavailable). The 6.7% short interest remains modest, suggesting limited squeeze dynamics, but the elevated momentum reading combined with unprofitability raises questions about whether enthusiasm for its surgical glaucoma devices has outpaced fundamental delivery. The absence of earnings power makes this a confidence-driven story vulnerable to sentiment shifts, particularly if medical device demand softens or competitive pressures mount.